Evidence outlook
Approved: Non-Small Cell Lung Cancer, Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma, Recurrent Glioblastoma, Ovarian Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (1)
- III or IV disease following initial surgical resection ( 1.6 ) o in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
FDA may approve a biosimilar for an indication without a clinical study in that indication, based on the reference product's evidence. The reference product's trials are on its page: Bevacizumab.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other VEGF-A drugs
Aflibercept, aflibercept-abzv (Enzeevu), aflibercept-ayyh (Pavblu), aflibercept-boav (Eydenzelt), aflibercept-jbvf (Yesafili) and 33 more. Compare all 39 VEGF-A drugs
This mechanism is crowded: 38 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Jobevne (bevacizumab-Nwgd): this drug | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eylea) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Abzv (Enzeevu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Ayyh (Pavblu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Boav (Eydenzelt) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Jbvf (Yesafili) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Mrbb (Ahzantive) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Yszy (Opuviz) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Brolucizumab-Dbll | Approved(overall) | Antibody fragment | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Encorafenib | Approved | Small molecule | BRAF V600E | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Approved | Small molecule | VEGFR1/2/3 | Reliable signal | NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001 | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Weak signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7) | |
| Ranibizumab (Lucentis) | Approved(overall) | Antibody fragment | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Eqrn (Cimerli) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Hkdz (Ranluspec) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Leyk (Nufymco) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Nuna (Byooviz) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016) | |
| Sotorasib | Approved | Small molecule | KRAS G12C | not yet graded | No reviewed efficacy summary in this indication | |
| Tucatinib | Approved | Small molecule | HER2 | Partial signal | NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT5906 | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| CKD-701 (Lucenbies) | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| HLX04-O | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ximluci) | Phase 3(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Surabgene Lomparvovec | Phase 3(overall) | Gene therapy / editing | VEGF-A | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Tarcocimab Tedromer | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Telisotuzumab Adizutecan | Phase 3 | Antibody–drug conjugate | MET | not yet graded | No reviewed efficacy summary in this indication | |
| MW02 | Phase 2/3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Bafisontamab | Phase 2 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Pelareorep | Phase 2 | Oncolytic virus | Tumor cells (oncolytic replication) | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rimmyrah) | Phase 1(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Afiveg) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Eyluxvi) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Mynzepli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Vgenfli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ranivisio) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rexatilux) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Telbermin | Discontinued | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.